Trial
NCT02113891
Eculizumab Therapy for Subclinical Antibody-mediated Rejection in Kidney Transplantation
Phase IWITHDRAWNOTHER/UNKNOWNConfidence: LOW
Sponsor
Assistance Publique - Hôpitaux de Paris
Collaborators
Institut National de la Santé Et de la Recherche Médicale, France; Alexion Pharmaceuticals, Inc.; URC-CIC Paris Descartes Necker Cochin
Condition
Subclinical Acute Antibody-mediated Rejection in Kidney Transplantation
Intervention
Eculizumab
Why stopped
disengagement of the sponsor Alexion Pharmaceuticals
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2025-11-20